Mural Oncology plc (NASDAQ:MURA - Free Report) - Analysts at HC Wainwright lowered their Q1 2025 earnings per share estimates for Mural Oncology in a research report issued to clients and investors on Wednesday, March 12th. HC Wainwright analyst A. Maldonado now expects that the company will earn ($2.13) per share for the quarter, down from their prior estimate of ($2.05). HC Wainwright currently has a "Buy" rating and a $18.00 target price on the stock. The consensus estimate for Mural Oncology's current full-year earnings is ($7.54) per share. HC Wainwright also issued estimates for Mural Oncology's Q2 2025 earnings at ($1.26) EPS, Q3 2025 earnings at ($1.17) EPS, Q4 2025 earnings at ($1.10) EPS, FY2025 earnings at ($5.65) EPS, FY2026 earnings at ($3.81) EPS, FY2027 earnings at ($3.41) EPS, FY2028 earnings at ($2.27) EPS and FY2029 earnings at ($1.45) EPS.
Mural Oncology (NASDAQ:MURA - Get Free Report) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($2.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.96) by ($0.05). During the same quarter in the previous year, the firm posted ($3.57) earnings per share.
Mural Oncology Trading Down 5.8 %
Shares of NASDAQ MURA traded down $0.24 during trading hours on Monday, reaching $3.87. The stock had a trading volume of 151,118 shares, compared to its average volume of 158,736. The firm has a market cap of $66.67 million, a price-to-earnings ratio of -0.42 and a beta of 3.66. The business's fifty day moving average price is $3.91 and its two-hundred day moving average price is $3.61. Mural Oncology has a 52-week low of $2.87 and a 52-week high of $5.12.
Institutional Trading of Mural Oncology
Large investors have recently modified their holdings of the company. Geode Capital Management LLC lifted its holdings in Mural Oncology by 2.6% during the third quarter. Geode Capital Management LLC now owns 190,056 shares of the company's stock worth $595,000 after buying an additional 4,731 shares during the period. FMR LLC lifted its holdings in Mural Oncology by 124.7% during the third quarter. FMR LLC now owns 20,580 shares of the company's stock worth $64,000 after buying an additional 11,423 shares during the period. Point72 Asset Management L.P. purchased a new stake in Mural Oncology during the third quarter worth $340,000. Commerce Bank purchased a new stake in Mural Oncology during the third quarter worth $39,000. Finally, Jane Street Group LLC purchased a new stake in Mural Oncology during the fourth quarter worth $68,000. Hedge funds and other institutional investors own 80.21% of the company's stock.
About Mural Oncology
(
Get Free Report)
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Featured Stories
Before you consider Mural Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mural Oncology wasn't on the list.
While Mural Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
